GAITHERSBURG, Maryland – Anyone responsible for delivering news to those who invest in shares of Edwards Lifesciences (Irvine, California) might have resorted to the cliché, "I have some good news and I have some bad news." The good news is that an FDA advisory committee voted 9-0 (with one abstention) that the benefits outweigh the risks associated with the firm's Sapien aortic valve, an outcome that was anticipated by the markets after FDA posted documents associated with the application earlier this week (Medical Device Daily, July 19, 2011). (Medical Device Daily) Read More
